Attached files
| file | filename |
|---|---|
| EX-21.1 - EX-21.1 - Aeglea BioTherapeutics, Inc. | agle-ex211_888.htm |
| EX-32.2 - EX-32.2 - Aeglea BioTherapeutics, Inc. | agle-ex322_6.htm |
| EX-32.1 - EX-32.1 - Aeglea BioTherapeutics, Inc. | agle-ex321_13.htm |
| EX-31.2 - EX-31.2 - Aeglea BioTherapeutics, Inc. | agle-ex312_14.htm |
| EX-31.1 - EX-31.1 - Aeglea BioTherapeutics, Inc. | agle-ex311_11.htm |
| EX-4.5 - EX-4.5 - Aeglea BioTherapeutics, Inc. | agle-ex45_732.htm |
| 10-K - 10-K - Aeglea BioTherapeutics, Inc. | agle-10k_20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-228967) and Form S-8 (No. 333-210633, 333-216903, 333-223614 and 333-230137) of Aeglea BioTherapeutics, Inc. of our report dated February 24, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Austin, Texas
February 24, 2020